Distilled Insider — May 11, 2026

Insider Signal Report — 2026-05-11

Scan covers trade_date 2026-05-062026-05-11 | 19 qualifying trades scanned | 2 signals detected


★★★★ Informed Accumulation

Criteria: Repeat Buyer + Prior 30d −10% to −20%

Insider with a prior purchase in the same ticker within 2 years, adding to position after a 10–20% pullback. Deep institutional knowledge + deliberate price discipline. EV ~20–30%+ at 12–15m. Cross-check business quality — serial buyers into structural decline are noise.

Target Hold: 12–15 months

TickerCompanyTrade DateInsiderTitleValuePrior 30dC-SuiteNew PosAlso Qualifies
WTWWILLIS TOWERS WATSON PLC2026-05-06Clarke LucyPresident of Risk & Broking$499K-13.3%

★★★ Momentum Confirmation

Criteria: Insider Buy After >+10% Prior Month

Any insider buying ≥$200k after the stock already moved up >10% in the prior month. Counter-intuitive but data-backed: exec sees real fundamental improvement behind the move. EV +17–34% through 9m — exit at 9m as performance degrades past that point.

Target Hold: 6–9 months

TickerCompanyTrade DateInsiderTitleValuePrior 30dC-SuiteNew PosAlso Qualifies
OPENOpendoor Technologies Inc.2026-05-11Nejatian KasraChief Executive Officer$488K+11.2%

Notable Buys — No Strategy Match

Trades ≥$500,000 that didn't meet any strategy filter. Often in the −5% to 0% prior-return zone (weakest bucket) or missing price data.

TickerCompanyTrade DateInsiderTitleValuePrior 30dC-SuiteNew PosAlso Qualifies
ODTXOdyssey Therapeutics, Inc.2026-05-08Dimension Capital II, L.P.maybe director$20.0MN/A
GEHCGE HealthCare Technologies Inc.2026-05-06CULP H LAWRENCE JRmaybe director$5.0M-12.3%
UPSTUpstart Holdings, Inc.2026-05-07Girouard Davemaybe director$5.0M+9.6%
POOLPOOL CORP2026-05-07PEREZ DE LA MESA MANUEL Jmaybe director$1.9M-5.5%
COAGHemab Therapeutics Holdings, Inc.2026-05-06Kolchinsky Petermaybe director$1.7MN/A
COAGHemab Therapeutics Holdings, Inc.2026-05-06RA Capital Healthcare Fund LPmaybe director$1.7MN/A
COAGHemab Therapeutics Holdings, Inc.2026-05-06RA Capital Nexus Fund II, L.P.maybe director$1.7MN/A
COAGHemab Therapeutics Holdings, Inc.2026-05-06RA Capital Nexus Fund IV, L.P.maybe director$1.7MN/A
COAGHemab Therapeutics Holdings, Inc.2026-05-06Shah Rajeev M.maybe director$1.7MN/A
ADPAUTOMATIC DATA PROCESSING INC2026-05-07SWAN ROBERT HOLMESmaybe director$746K+5.1%
NCLHNorwegian Cruise Line Holdings Ltd.2026-05-07Byng-Thorne Zillahmaybe director$521K-8.1%

Signal Summary

RatingStrategySignals
★★★★★Conviction Bottom0
★★★★Informed Accumulation1
★★★★Fresh Conviction Entry0
★★★Momentum Confirmation1
★★Fallen Knife w/ Insider Backstop0

Generated 2026-05-11 · Strategies based on backtests 2021–2026 on US insider purchases

This content is for informational purposes only and does not constitute financial, investment, or trading advice. Always consult a qualified financial professional before making any investment decisions.